46 results on '"Hansen, Cecilie Bo"'
Search Results
2. Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
3. Humoral and cellular immune responses eleven months after the third dose of BNT162b2 an mRNA-based COVID-19 vaccine in people with HIV – a prospective observational cohort study
4. High anti-SARS-CoV-2 seroprevalence among unvaccinated mother–child pairs from a rural setting in north-eastern Tanzania during the second wave of COVID-19
5. The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines
6. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors
7. Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies
8. Diverging humoral and cellular immune responses due to Omicron—a national study from the Faroe Islands
9. Distinguishing SARS-CoV-2 infection and vaccine responses up to 18 months post-infection using nucleocapsid protein and receptor-binding domain antibodies
10. Expression of complement C3, C5, C3aR and C5aR1 genes in resting and activated CD4+ T cells
11. Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies.
12. Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis
13. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies
14. Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination
15. SARS‐CoV‐2 antibody dynamics over time and risk factors associated with infection and long COVID‐19 symptoms in large working environments
16. Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study
17. Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection
18. Lectin Pathway Enzyme MASP-2 and Downstream Complement Activation in COVID-19
19. Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases
20. Lectin Pathway Enzyme MASP-2 and Downstream Complement Activation in COVID-19.
21. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls
22. Antibody Responses and Risk Factors Associated With Impaired Immunological Outcomes Following Two Doses of BNT162b2 COVID-19 Vaccination in Patients With Chronic Pulmonary Diseases
23. Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3
24. Humoral response to two doses of BNT162b2 vaccination in people with HIV
25. Increase in the Complement Activation Product C4d and the Terminal Complement Complex sC5b-9 Is Associated with Disease Severity and a Fatal Outcome in Necrotizing Soft-Tissue Infection
26. The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice
27. SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation
28. Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants
29. Normal T and B Cell Responses Against SARS-CoV-2 in a Family With a Non-Functional Vitamin D Receptor: A Case Report
30. Author response: The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice
31. Antibody‐dependent neutralizing capacity of the SARS‐CoV‐2 vaccine BNT162b2 with and without previous COVID‐19 priming
32. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain
33. SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands
34. Increase in the Complement Activation Product C4d and the Terminal Complement Complex sC5b-9 Is Associated with Disease Severity and a Fatal Outcome in Necrotizing Soft-Tissue Infection.
35. SARS-CoV-2 natural antibody response persists up to 12 months in a nationwide study from the Faroe Islands
36. Humoral response to two doses of BNT162b2 vaccination in people with HIV.
37. SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals
38. SARS-CoV-2 antibody responses determine disease severity in COVID-19 infected individuals
39. Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections—A Prospective Observational Study
40. Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3
41. A time dependent gene expression level of C3, C3aR and CTSL in CD4+ T cells
42. The Levels of the Lectin Pathway Serine Protease MASP-1 and Its Complex Formation with C1 Inhibitor Are Linked to the Severity of Hereditary Angioedema
43. Humoral immunity after a booster dose of COVID-19 vaccine in patients with psoriasis treated with methotrexate and biologics: a cohort study.
44. COVID-19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post-Pandemic Concerns About the Impact of Rituximab.
45. SARS-CoV-2 anti-RBD and anti-N protein responses are differentially regulated between mother-child pairs: insight from a national study cohort at the Faroe Islands.
46. Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.